These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
    Author: Gong ZJ, Ren JQ, Kong G, Qing DJ, Liu H, Liang YQ.
    Journal: Ai Zheng; 2007 Dec; 26(12):1350-3. PubMed ID: 18076799.
    Abstract:
    BACKGROUND & OBJECTIVE: Recently, some scholars advocate perioperative chemotherapy for colorectal cancer. This study aimed to investigate the impact of perioperative chemotherapy on the prognosis of colorectal cancer. METHODS: From Aug. 2001 to Aug. 2003, 167 patients with Dukes'B or C colorectal cancer were randomized into two groups: 82 in trial group received perioperative chemotherapy using 5-fluorouracil (5-FU), while 85 in control group received no perioperative chemotherapy. All patients received adjuvant chemotherapy of 5-FU/leucovorin regimen. The adverse events, recurrence rate and survival rate were compared between these two groups. RESULTS: There was no difference in adverse events between the two groups. The overall recurrence rate was 42.5%û it was significantly lower in trial group than in control group (34.6% vs. 49.4%, P=0.038). The overall 1-, 3-, and 4-year survival rates were 97.6%, 74.7% and 61.8%û they were significantly higher in trial group than in control group (100% vs. 95.3%, 82.7% vs. 67.1%, and 69.1% vs. 54.8%, P=0.046). CONCLUSION: Perioperative chemotherapy can improve the prognosis of colorectal cancer.
    [Abstract] [Full Text] [Related] [New Search]